{"title":"A review on mTOR inhibitor use and outcomes of COVID-19 among patients with kidney transplantation.","authors":"Sawai Singh Rathore, Vanessa Vidaurre Corrales, Ashwin Hassan Gopala, Hamam Aneis, Ibrahim Marouf Yasin Al Shyyab, Mutaz AlBeetar, Samah Mohamed Kannas, Omar Jihad Saleh Almistarihi, Mohamed Hamed Daoud","doi":"10.6026/973206300211447","DOIUrl":null,"url":null,"abstract":"<p><p>Kidney transplant recipients are at increased risk of severe COVID-19 due to immunosuppression and the impact of mTOR inhibitors on outcomes remains unclear. Hence, we evaluated 24 observational studies with 5,882 kidney transplant patients to assess the association of mTOR inhibitors with COVID-19 severity and mortality. Random-effects models showed that mTOR inhibitors were significantly associated with reduced mortality (OR=0.63, 95% CI 0.48-0.83, P=0.001) but not with COVID-19 severity (OR=0.70, 95% CI 0.41-1.20, P=0.865). Thus, mTOR inhibitors may provide a survival benefit in kidney transplant patients with COVID-19, highlighting the need for further research.</p>","PeriodicalId":8962,"journal":{"name":"Bioinformation","volume":"21 6","pages":"1447-1453"},"PeriodicalIF":1.9000,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12449486/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioinformation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.6026/973206300211447","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Kidney transplant recipients are at increased risk of severe COVID-19 due to immunosuppression and the impact of mTOR inhibitors on outcomes remains unclear. Hence, we evaluated 24 observational studies with 5,882 kidney transplant patients to assess the association of mTOR inhibitors with COVID-19 severity and mortality. Random-effects models showed that mTOR inhibitors were significantly associated with reduced mortality (OR=0.63, 95% CI 0.48-0.83, P=0.001) but not with COVID-19 severity (OR=0.70, 95% CI 0.41-1.20, P=0.865). Thus, mTOR inhibitors may provide a survival benefit in kidney transplant patients with COVID-19, highlighting the need for further research.
由于免疫抑制，肾移植受者发生严重COVID-19的风险增加，mTOR抑制剂对结果的影响尚不清楚。因此，我们评估了涉及5,882例肾移植患者的24项观察性研究，以评估mTOR抑制剂与COVID-19严重程度和死亡率的关系。随机效应模型显示，mTOR抑制剂与降低死亡率显著相关（OR=0.63, 95% CI 0.48-0.83， P=0.001），但与COVID-19严重程度无关（OR=0.70, 95% CI 0.41-1.20， P=0.865）。因此，mTOR抑制剂可能为肾移植患者COVID-19提供生存益处，这突出了进一步研究的必要性。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
